What question did this study set out to answer?

To assess the role of lipoprotein(a) as a significant yet underrecognized cardiovascular risk biomarker.

January 10, 2026International Journal of Molecular SciencesOpen Access

Elevated Lp(a) linked to greater ASCVD risk, particularly in premature events.

View Full Paper

Ask AI

Bookmark

Why the study?

Many cardiovascular events occur despite normal LDL-C levels, and Lp(a) remains underrecognized and inconsistently measured in clinical practice despite being an independent, genetically determined risk factor.

Design

Minireview

Key result

Elevated Lp(a) levels are independently associated with greater risk of atherosclerotic cardiovascular disease, particularly in premature events.

Authors

PFPietro Formisano EVElena Vianello EDElena Dozio

Discussion

Member takes

Overview

Supports Lp(a) inclusion in ASCVD risk assessment; leaves open standardization and therapy outcome trials.

Key Points

To assess the role of lipoprotein(a) as a significant yet underrecognized cardiovascular risk biomarker.
Summarizes current knowledge on elevated Lp(a) mechanisms.
Discusses clinical implications for cardiovascular risk assessment.
Highlights the need for standardized Lp(a) measurement in clinical practice.
Elevated Lp(a) levels correlate with higher risks of atherosclerotic cardiovascular diseases.
Identified mechanisms include pro-atherogenic and pro-inflammatory effects.
Emphasized the importance of Lp(a)-targeted therapies in clinical practice.

Cite This Study

Formisano et al. (2025) studied this question. Elevated Lp(a) levels are independently associated with greater risk of atherosclerotic cardiovascular disease, particularly in premature events.

synapsesocial.com/papers/6963221b91e05aa366cb89b6 https://doi.org/10.3390/ijms27010290

View Full Paper

Ask AI

Bookmark

January 10, 2026International Journal of Molecular SciencesOpen Access

Elevated Lp(a) linked to greater ASCVD risk, particularly in premature events.

View Full Paper

Ask AI

Bookmark

Why the study?

Design

Minireview

Key result

Elevated Lp(a) levels are independently associated with greater risk of atherosclerotic cardiovascular disease, particularly in premature events.

Authors

PFPietro Formisano EVElena Vianello EDElena Dozio

Discussion

Member takes

Overview

Supports Lp(a) inclusion in ASCVD risk assessment; leaves open standardization and therapy outcome trials.

Key Points

To assess the role of lipoprotein(a) as a significant yet underrecognized cardiovascular risk biomarker.
Summarizes current knowledge on elevated Lp(a) mechanisms.
Discusses clinical implications for cardiovascular risk assessment.
Highlights the need for standardized Lp(a) measurement in clinical practice.
Elevated Lp(a) levels correlate with higher risks of atherosclerotic cardiovascular diseases.
Identified mechanisms include pro-atherogenic and pro-inflammatory effects.
Emphasized the importance of Lp(a)-targeted therapies in clinical practice.

Cite This Study

Formisano et al. (2025) studied this question. Elevated Lp(a) levels are independently associated with greater risk of atherosclerotic cardiovascular disease, particularly in premature events.

synapsesocial.com/papers/6963221b91e05aa366cb89b6 https://doi.org/10.3390/ijms27010290

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark